Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
3.
Bone ; 91: 186-93, 2016 10.
Article in English | MEDLINE | ID: mdl-27497735

ABSTRACT

Type 2 diabetes mellitus increases skeletal fragility; however, the contributing mechanisms and optimal treatment strategies remain unclear. We studied the effects of diabetes and insulin therapy on non-enzymatic glycation (NEG), cortical porosity (Ct.Po) and biomechanics of the bone tissue in Zucker Diabetic Fatty (ZDF) rats. Eleven-week old ZDF diabetic and non-diabetic rats were given insulin to achieve glycaemic control or vehicle seven days per week over twelve weeks (insulin dose adapted individually 0.5 international units (IU) at week 1 to 13.0IU at week 12). The right femora were excised, micro-CT scanned, and tested in 3-point bending to measure biomechanics. NEG of the midshaft was determined from bulk fluorescence. Diabetes led to increased NEG (+50.1%, p=0.001) and Ct.Po (+22.9%, p=0.004), as well as to reduced mechanical competence (max. stress: -14.2%, p=0.041, toughness: -29.7%, p=0.016) in the bone tissue. NEG and Ct.Po both correlated positively to serum glucose (NEG: R(2)=0.41, p<0.001, Ct.Po: R(2)=0.34, p=0.003) and HbA1c (NEG: R(2)=0.42, p<0.001, Ct.Po: R(2)=0.28, p=0.008) levels, while NEG correlated negatively with bone biomechanics (elastic modulus: R(2)=0.21, p=0.023, yield stress: R(2)=0.17, p=0.047). Twelve weeks of insulin therapy had no significant effect on NEG or Ct.Po, and was unable to improve the mechanical competence of the bone tissue. A reduction of mechanical competence was observed in the bone tissue of the diabetic rats, which was explained in part by increased collagen NEG. Twelve weeks of insulin therapy did not alter NEG, Ct.Po or bone biomechanics. However, significant correlations between NEG and serum glucose and HbA1c were observed, both of which were reduced with insulin therapy. This suggests that a longer duration of insulin therapy may be required to reduce the NEG of the bone collagen and restore the mechanical competence of diabetic bone.


Subject(s)
Bone and Bones/physiopathology , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/physiopathology , Insulin/therapeutic use , Animals , Biomechanical Phenomena , Blood Glucose/metabolism , Bone Density/drug effects , Bone Remodeling/drug effects , Bone and Bones/diagnostic imaging , Bone and Bones/drug effects , Cortical Bone/diagnostic imaging , Cortical Bone/drug effects , Cortical Bone/pathology , Cortical Bone/physiopathology , Diabetes Mellitus, Type 2/blood , Femur/diagnostic imaging , Femur/drug effects , Femur/pathology , Femur/physiopathology , Glycated Hemoglobin/metabolism , Glycosylation , Insulin/pharmacology , Male , Minerals/metabolism , Porosity , Rats, Zucker
4.
Cell Death Dis ; 7: e2119, 2016 Feb 25.
Article in English | MEDLINE | ID: mdl-26913608

ABSTRACT

The Wnt inhibitor Dickkopf-1 (DKK-1) has been associated with the occurrence of bone metastases in osteotropic prostate cancer by inhibiting osteoblastogenesis. P38 mitogen-activated protein kinase (MAPK) activity is also dysregulated in advanced prostate cancer. However, the impact of p38 MAPK signaling on DKK-1 remains unknown. Inhibition of p38 MAPK signaling in osteolytic PC3 cells by small molecule inhibitors (doramapimod, LY2228820 and SB202190) suppressed DKK-1 expression, whereas activation of p38 MAPK by anisomycin increased DKK-1. Further dissection by targeting individual p38 MAPK isoforms with siRNA revealed a stronger role for MAPK11 than MAPK14 and MAPK12 in the regulation of DKK-1. Moreover, prostate cancer cells with a predominantly osteolytic phenotype produced sufficient amounts of DKK-1 to inhibit Wnt3a-induced osteoblastic differentiation in C2C12 cells. This inhibition was blocked directly by neutralizing DKK-1 using a specific antibody and also indirectly by blocking p38 MAPK. Furthermore, tissue expression in human prostate cancer revealed a correlation between p38 MAPK and DKK-1 expression with higher expression in tumor compared with normal tissues. These results reveal that p38 MAPK regulates DKK-1 in prostate cancer and may present a potential target in osteolytic prostate cancers.


Subject(s)
Intercellular Signaling Peptides and Proteins/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism , Antibodies, Neutralizing/immunology , Cell Differentiation , Cell Line, Tumor , Down-Regulation/drug effects , Humans , Imidazoles/pharmacology , Intercellular Signaling Peptides and Proteins/genetics , Intercellular Signaling Peptides and Proteins/immunology , Male , Mitogen-Activated Protein Kinase 11/antagonists & inhibitors , Mitogen-Activated Protein Kinase 11/genetics , Mitogen-Activated Protein Kinase 11/metabolism , Mitogen-Activated Protein Kinase 12/antagonists & inhibitors , Mitogen-Activated Protein Kinase 12/genetics , Mitogen-Activated Protein Kinase 12/metabolism , Mitogen-Activated Protein Kinase 14/antagonists & inhibitors , Mitogen-Activated Protein Kinase 14/genetics , Mitogen-Activated Protein Kinase 14/metabolism , Naphthalenes/pharmacology , Prostatic Neoplasms , Pyrazoles/pharmacology , Pyridines/pharmacology , RNA Interference , RNA, Messenger/metabolism , RNA, Small Interfering , Signal Transduction/drug effects , Wnt3A Protein/genetics , Wnt3A Protein/metabolism , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/genetics
5.
Osteoporos Int ; 27(2): 719-27, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26264603

ABSTRACT

UNLABELLED: In two large German population-based cohorts, we showed positive associations between serum thyrotropin (TSH) concentrations and the Fracture Risk Assessment score (FRAX) in men and positive associations between TSH concentrations and bone turnover markers in women. INTRODUCTION: The role of thyroid hormones on bone stiffness and turnover is poorly defined. Existing studies are confounded by differences in design and small sample size. We assessed the association between TSH serum concentrations and bone stiffness and turnover in the SHIP cohorts, which are two population-based cohorts from a region in Northern Germany comprising 2654 men and women and 3261 men and women, respectively. METHODS: We calculated the bone stiffness index using quantitative ultrasound (QUS) at the calcaneus, employed FRAX score for assessment of major osteoporotic fractures, and measured bone turnover markers, N-terminal propeptide of type I procollagen (P1NP), bone-specific alkaline phosphatase (BAP), osteocalcin, and type I collagen cross-linked C-telopeptide (CTX) in all subjects and sclerostin in a representative subgroup. RESULTS: There was no association between TSH concentrations and the stiffness index in both genders. In men, TSH correlated positively with the FRAX score both over the whole TSH range (p < 0.01) and within the reference TSH range (p < 0.01). There were positive associations between TSH concentrations and P1NP, BAP, osteocalcin, and CTX (p < 0.01) in women but not in men. There was no significant association between TSH and sclerostin levels. CONCLUSIONS: TSH serum concentrations are associated with gender-specific changes in bone turnover and stiffness.


Subject(s)
Bone Density/physiology , Bone Remodeling/physiology , Thyrotropin/blood , Adult , Aged , Aged, 80 and over , Anthropometry/methods , Biomarkers/blood , Calcaneus/diagnostic imaging , Cohort Studies , Female , Health Surveys , Humans , Male , Middle Aged , Osteoporotic Fractures/blood , Osteoporotic Fractures/etiology , Osteoporotic Fractures/physiopathology , Risk Assessment/methods , Sex Characteristics , Ultrasonography/methods
6.
Bone ; 82: 116-21, 2016 Jan.
Article in English | MEDLINE | ID: mdl-25952971

ABSTRACT

Type 2 diabetes mellitus increases skeletal fragility; however, the contributing mechanisms and the efficacy of bone-forming agents are unclear. We studied diabetes and parathyroid hormone (PTH) treatment effects on cortical porosity (Ct.Po), non-enzymatic glycation (NEG) and bone mechanics in Zucker diabetic fatty (ZDF) rats. Eleven-week old ZDF diabetic (DB) and non-diabetic (ND) rats were given 75µg/kg PTH (1-84) or vehicle 5days per week over 12weeks. The right femora and L4 vertebrae were excised, micro-CT scanned, and tested in 3-point bending and uniaxial compression, respectively. NEG of the samples was determined using fluorescence. Diabetes increased Ct.Po (vertebra (vert): +40.6%, femur (fem): +15.5% vs. ND group, p<0.05) but had no effect on NEG. PTH therapy reduced vertebral NEG in the ND animals only (-73% vs untreated group, p<0.05), and increased femoral NEG in the DB vs. ND groups (+63%, p<0.05). PTH therapy had no effect on Ct.Po. Diabetes negatively affected bone tissue mechanics where reductions in vertebral maximum strain (-22%) and toughness (-42%) were observed in the DB vs. ND group (p<0.05). PTH improved maximum strain in the vertebra of the ND animals (+21%, p<0.05) but did not have an effect in the DB group. PTH increased femoral maximum strain (+21%) and toughness (+28%) in ND and decreased femoral maximum stress (-13%) and toughness (-27%) in the DB animals (treated vs. untreated, p<0.05). Ct.Po correlated negatively with maximum stress (fem: R=-0.35, p<0.05, vert: R=-0.57, p<0.01), maximum strain (fem: R=-0.35, p<0.05, vert: R=-0.43, p<0.05) and toughness (fem: R=-0.34, p<0.05, vert: R=-0.55, p<0.01), and NEG correlated negatively with toughness at the femur (R=-0.34, p<0.05) and maximum strain at the vertebra (R=-0.49, p<0.05). Diabetes increased cortical porosity and reduced bone mechanics, which were not improved with PTH treatment. PTH therapy alone may worsen diabetic bone mechanics through formation of new bone with high AGEs cross-linking. Optimal treatment regimens must address both improvements of bone mass and glycemic control in order to successfully reduce diabetic bone fragility. This article is part of a Special Issue entitled "Bone and diabetes".


Subject(s)
Bone Density/drug effects , Bone Density/physiology , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Parathyroid Hormone/therapeutic use , Animals , Bone and Bones/drug effects , Bone and Bones/metabolism , Glycation End Products, Advanced/metabolism , Glycosylation/drug effects , Male , Parathyroid Hormone/pharmacology , Porosity/drug effects , Rats , Rats, Zucker , Treatment Outcome
7.
Bone ; 82: 108-15, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26055107

ABSTRACT

Zucker Diabetic Fatty (ZDF) rats represent an established model of type 2 diabetes mellitus (T2DM) and display several features of human diabetic bone disease, including impaired osteoblast function, decreased bone strength, and delayed bone healing. Here, we determined whether glycemic control by insulin treatment prevents skeletal complications associated with diabetes. Subcritical femur defects were created in diabetic (fa/fa) and non-diabetic (+/+) ZDF rats. Diabetic rats were treated once daily with long-lasting insulin glargin for 12weeks for glycemic control. Insulin treatment successfully maintained serum levels of glycated hemoglobin, while untreated diabetic rats showed a 2-fold increase. Trabecular and cortical bone mass measured by µCT were decreased in diabetic rats. Insulin treatment increased bone mass of the cortical, but not of the trabecular bone compartment. Dynamic histomorphometry revealed a lower bone formation rate at the trabecular and periosteal cortical bone in diabetic animals and decreased serum procollagen type 1 N-terminal propeptide (P1NP, -49%) levels. Insulin treatment partially improved these parameters. In T2DM, serum levels of tartrate-resistant acid phosphatase (TRAP, +32%) and C-terminal telopeptide (CTX, +49%) were increased. Insulin treatment further elevated TRAP levels, but did not affect CTX levels. While diabetes impaired bone defect healing, glycemic control with insulin fully reversed these negative effects. In conclusion, insulin treatment reversed the adverse effects of T2DM on bone defect regeneration in rats mainly by improving osteoblast function and bone formation. This article is part of a Special Issue entitled Bone and diabetes.


Subject(s)
Bone Density/drug effects , Bone Regeneration/drug effects , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Insulin/therapeutic use , Animals , Bone Density/physiology , Bone Regeneration/physiology , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Diabetes Mellitus, Type 2/pathology , Insulin/pharmacology , Male , Rats , Rats, Zucker
8.
Handchir Mikrochir Plast Chir ; 47(4): 228-34, 2015 Aug.
Article in German | MEDLINE | ID: mdl-26287325

ABSTRACT

MOTIVATION: Occupational injuries cause short-term, direct costs as well as long-term follow-up costs over the lifetime of the casualties. Due to shrinking budgets accident insurance companies focus on cost reduction programmes and prevention measures. For this reason, a decision support system for consequential cost calculation of occupational injuries was developed for the main Austrian social occupational insurance institution (AUVA) during three projects. METHODS: This so-called cost calculation tool combines the traditional instruments of accounting with quantitative methods such as micro-simulation. The cost data are derived from AUVA-internal as well as external economic data sources. Based on direct and indirect costs, the subsequent occupational accident costs from the time of an accident and, if applicable, beyond the death of the individual casualty are predicted for the AUVA, the companies in which the casualties are working, and the other economic sectors. RESULTS: By using this cost calculation tool, the AUVA classifies risk groups and derives related prevention campaigns. In the past, the AUVA concentrated on falling, accidents at construction sites and in agriculture/forestry, as well as commuting accidents. Currently, among others, a focus on hand injuries is given and first prevention programmes have been initiated. Hand injuries represent about 38% of all casualties with average costs of about 7,851 Euro/case. Main causes of these accidents are cutting injuries in production, agriculture, and forestry. Beside a low, but costly, number of amputations with average costs of more than 100,000 Euro/case, bone fractures and strains burden the AUVA-budget with about 17,500 and 10,500 € per case, respectively. CONCLUSION: Decision support systems such as this cost calculation tool represent necessary instruments to identify risk groups and their injured body parts, causes of accidents, and economic activities, which highly burden the budget of an injury company, and help derive countermeasures to avoid injuries. Target-group specific, suitable prevention measures for hand injuries can reduce accidents in a cost-effective way and lower their consequences.


Subject(s)
Costs and Cost Analysis/economics , Hand Injuries/economics , Hand Injuries/prevention & control , Health Care Costs/statistics & numerical data , Insurance, Accident/economics , National Health Programs/economics , Occupational Injuries/economics , Occupational Injuries/prevention & control , Workers' Compensation/economics , Austria , Causality , Cost-Benefit Analysis/economics , Costs and Cost Analysis/statistics & numerical data , Cross-Sectional Studies , Disability Evaluation , Hand Injuries/epidemiology , Humans , Occupational Injuries/epidemiology
9.
Leukemia ; 29(2): 259-68, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25394715

ABSTRACT

Myelodysplastic syndromes (MDSs) represent clonal disorders mainly of the elderly that are characterized by ineffective hematopoiesis and an increased risk of transformation into acute myeloid leukemia. The pathogenesis of MDS is thought to evolve from accumulation and selection of specific genetic or epigenetic events. Emerging evidence indicates that MDS is not solely a hematopoietic disease but rather affects the entire bone marrow microenvironment, including bone metabolism. Many of these cells, in particular mesenchymal stem and progenitor cells (MSPCs) and osteoblasts, express a number of adhesion molecules and secreted factors that regulate blood regeneration throughout life by contributing to hematopoietic stem and progenitor cell (HSPC) maintenance, self-renewal and differentiation. Several endocrine factors, such as erythropoietin, parathyroid hormone and estrogens, as well as deranged iron metabolism modulate these processes. Thus, interactions between MSPC and HSPC contribute to the pathogenesis of MDS and associated pathologies. A detailed understanding of these mechanisms may help to define novel targets for diagnosis and possibly therapy. In this review, we will discuss the scientific rationale of 'osteohematology' as an emerging research field in MDS and outline clinical implications.


Subject(s)
Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/pathology , Animals , Bone Marrow/pathology , Cytokines/metabolism , Disease Progression , Epigenesis, Genetic , Erythropoietin/metabolism , Hematopoietic Stem Cells/cytology , Humans , Iron/chemistry , Iron Overload/metabolism , Mesenchymal Stem Cells/cytology , Osteoblasts/cytology , Parathyroid Hormone/metabolism , Signal Transduction
10.
Bone ; 64: 281-7, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24780878

ABSTRACT

Cathepsin S is a cysteine protease that controls adipocyte differentiation and has been implicated in vascular and metabolic complications of obesity. Considering the inverse relation of osteoblasts and adipocytes and their mutual precursor cell, we hypothesized that cathepsin S may also affect osteoblast differentiation and bone remodeling. Thus, the fat and bone phenotypes of young (3 months old) and aged (12 or 18 months old) cathepsin S knock-out (KO) and wild-type (WT) mice were determined. Cathepsin S KO mice had a normal body weight at both ages investigated, even though the amount of subscapular and gonadal fat pads was reduced by 20%. Further, cathepsin S deficiency impaired adipocyte formation (-38%, p<0.001), which was accompanied by a lower expression of adipocyte-related genes and a reduction in serum leptin, IL-6 and CCL2 (p<0.001). Micro-CT analysis revealed an unchanged trabecular bone volume fraction and density, while tissue mineral density was significantly lower in cathepsin S KO mice at both ages. Aged KO mice further had a lower cortical bone mass (-2.3%, p<0.05). At the microarchitectural level, cathepsin S KO mice had thinner trabeculae (-8.3%), but a better connected trabecular network (+24%). Serum levels of the bone formation marker type 1 procollagen amino-terminal-propeptide and osteocalcin were both 2-3-fold higher in cathepsin S KO mice as was the mineralized surface. Consistently, osteogenic differentiation was increased 2-fold along with an increased expression of osteoblast-specific genes. Interestingly, serum levels of C-terminal telopeptide of type I collagen were also higher (+43%) in cathepsin S KO mice as were histological osteoclast parameters and ex vivo osteoclast differentiation. Thus, cathepsin S deficiency alters the balance between adipocyte and osteoblast differentiation, increases bone turnover, and changes bone microarchitecture. Therefore, bone and fat metabolisms should be monitored when using cathepsin S inhibitors clinically.


Subject(s)
Adipocytes/cytology , Bone Remodeling/physiology , Bone and Bones/ultrastructure , Cathepsins/physiology , Cell Differentiation/physiology , Osteoblasts/cytology , Animals , Mice , Mice, Knockout , Real-Time Polymerase Chain Reaction , X-Ray Microtomography
11.
Eur J Endocrinol ; 167(6): 873-80, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22968486

ABSTRACT

OBJECTIVE: To assess the association between abdominal aortic calcification (AAC) and serum levels of myostatin, a negative regulator of skeletal muscle mass, which has been implicated in the development of atherosclerotic lesions in mice. DESIGN AND PATIENTS: We assessed AAC semiquantitatively from the lateral spine scans obtained using dual energy X-ray absorptiometry in 1071 men aged 20-87 years. Serum myostatin levels were measured by an immunoassay that detects all myostatin forms. RESULTS: Total myostatin serum levels did not differ between men with or without self-reported ischemic heart disease, hypertension, or diabetes mellitus. Total serum myostatin levels were higher in men with higher serum calcium levels and lower in men with higher serum concentrations of highly sensitive C-reactive protein. Men with AAC had lower myostatin levels compared with men without AAC. Prevalence of AAC (AAC score > 0) was lower in the highest myostatin quartile compared with the three lower quartiles (P < 0.05). After adjustment for confounders, odds of AAC (AAC score > 0) were lower (OR=0.62; 95% confidence interval (95% CI), 0.45-0.85; P< 0.005) for the fourth myostatin quartile vs the three lower quartiles combined. In the sub-analysis of 745 men aged 60 years, the results were similar: AAC prevalence was lower in the highest myostatin quartile compared with the three lower quartiles combined (OR=0.54; 95% CI, 0.38-0.78; P<0.001). CONCLUSIONS: In older men, total myostatin serum levels are inversely correlated with AAC. Further studies are needed to investigate mechanisms underlying this association and to assess utility of myostatin as a cardiovascular marker.


Subject(s)
Aorta, Abdominal/pathology , Aortic Diseases/blood , Myostatin/blood , Vascular Calcification/blood , Absorptiometry, Photon , Aged , Aged, 80 and over , C-Reactive Protein/metabolism , Humans , Male , Middle Aged
12.
Z Rheumatol ; 71(10): 869-73, 2012 Dec.
Article in German | MEDLINE | ID: mdl-22806699

ABSTRACT

Rheumatoid arthritis (RA) is a bone-destructive disease that is a serious risk factor for the development of osteoporosis, which is defined by a loss in bone quality and an increased fracture risk. The proinflammatory cytokines tumor necrosis factor-α (TNFα), interleukin-6 (IL-6) and IL-17, in particular, contribute to local and systemic bone loss in RA. While effectively reducing inflammation, glucocorticoids add to the fracture risk. Therefore, an adequate supply of calcium and vitamin D is essential. For many patients with RA, bone density measurements are recommended.


Subject(s)
Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/drug therapy , Osteoporosis/drug therapy , Osteoporosis/etiology , Arthritis, Rheumatoid/diagnosis , Bone Density Conservation Agents/therapeutic use , Calcium/therapeutic use , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Osteoporosis/diagnosis , Treatment Outcome , Vitamin D/therapeutic use
13.
Horm Metab Res ; 44(6): 476-81, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22495973

ABSTRACT

Primary hyperparathyroidism (PHPT) is accompanied with a reduced bone mineral density (BMD) and an increased risk of fracture. Surgery is the only option for cure. It is hypothesized that in patients with PHPT bone metabolism normalizes after parathyroidectomy (PTX) and that BMD gradually increases. Fifty-two patients with PHPT who underwent surgery were prospectively followed for 1 year. Biochemical analyses were performed at baseline and 1, 4, 7 days; 6 weeks; and 3, 6, and 12 months, and BMD before and one year after surgery. Parathyroid hormone (PTH), calcium, and the bone resorption marker dropped immediately, but transiently after PTX, bone formation decreased more slowly. Osteoprotegerin (OPG) as well as cathepsin K did not show significant changes. BMD of the lumbar spine, but not of the femoral neck, increased significantly within one year after surgery. Moderate correlations existed between the changes of total calcium, ionized calcium, as well as bone-specific alkaline phosphatase and changes of the lumbar BMD. Patients who needed postoperative supplementation with calcium and vitamin D had significantly higher PTH levels. Some gender-specific differences in patients with PHPT were observed. In patients with PHPT, males appear to be more severely affected than females. Within the first year after PTX, bone metabolism normalized, and BMD of the lumbar spine increased. Patients who needed a supplementation with calcium and vitamin D after PTX preoperatively had higher serum levels of PTH.


Subject(s)
Bone and Bones/metabolism , Hyperparathyroidism, Primary/metabolism , Hyperparathyroidism, Primary/surgery , Postoperative Period , Preoperative Period , Alkaline Phosphatase/blood , Bone Density , Bone and Bones/physiopathology , Calcium/blood , Collagen Type I/blood , Dietary Supplements , Female , Humans , Hyperparathyroidism, Primary/blood , Hyperparathyroidism, Primary/physiopathology , Male , Middle Aged , Osteocalcin/blood , Parathyroid Hormone/blood , Parathyroidectomy , Peptides/blood , Phosphates/blood , Statistics, Nonparametric , Time Factors , Vitamin D/analogs & derivatives , Vitamin D/blood
14.
Horm Metab Res ; 43(13): 944-9, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22161252

ABSTRACT

Inhibition of the receptor activator of NF-κB ligand (RANKL) is a novel therapeutic option in the treatment of osteoporosis and related diseases. The aim of this study was to evaluate bone metabolism and structure in pigs after RANKL inhibition. 12 growing pigs were assigned to 2 groups with 6 animals each. The OPG group received recombinant human OPG-Fc (5 mg/kg IV) at day 0, the control group was given 0.9% NaCl solution. Serum levels of OPG-Fc, calcium (Ca), phosphorus (P), and bone turnover markers were evaluated every 5 days, and pigs were euthanized on day 20. Serum OPG-Fc concentration peaked at day 5 and coincided with significantly decreased Ca, P, and bone turnover markers. By day 15, measureable OPG-Fc serum levels could only be detected in 2/6 animals. With OPG-Fc clearance starting at day 10, serum Ca and P concentrations were not different between the 2 groups. TRACP5b, P1CP, and BAP levels significantly decreased by 40-70% relative to vehicle controls in the OPG-Fc group between days 5 and 10, indicating that pharmacologic concentration of OPG-Fc led to systemic concomitant inhibition of bone formation and resorption in young growing pigs. Dual X-ray absorptiometry data derived from the proximal femur did not differ between the 2 groups. µCT analysis of selected bone sites demonstrated an OPG-Fc-induced improvement of specific bone architectural indices and bone mineralization.


Subject(s)
Bone Resorption , Bone and Bones/metabolism , Calcium/blood , Immunoglobulin Fc Fragments/pharmacology , Osteoprotegerin/pharmacology , Absorptiometry, Photon , Alkaline Phosphatase/metabolism , Animals , Biomarkers/metabolism , Bone and Bones/diagnostic imaging , Female , Humans , Immunoglobulin Fc Fragments/genetics , Immunoglobulin Fc Fragments/metabolism , Male , Osteoprotegerin/genetics , Osteoprotegerin/metabolism , Phosphorus/blood , RANK Ligand/antagonists & inhibitors , RANK Ligand/metabolism , Swine
15.
Diabetologia ; 54(10): 2690-701, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21701818

ABSTRACT

AIMS/HYPOTHESIS: Vascular calcification is a prominent feature of both atherosclerosis and diabetes, and is clinically associated with osteoporosis. The expression of bone-regulatory factors and the impact of oxidative stress in aortic calcification are well-documented. Recently, nuclear factor of activated T cells (NFAT) cytoplasmic, calcineurin-dependent 1 (NFATc1) was identified in calcified aortic valves and has been implicated in vascular calcification. Therefore, we assessed the mechanisms of osteogenic transdifferentiation of vascular smooth muscle cells induced by oxidised LDL (oxLDL) and evaluated the role of NFAT in this process. METHODS: Human coronary artery smooth muscle cells (HCASMCs) were cultured for 21 days in medium supplemented with oxLDL. NFAT was inhibited using the NFAT inhibitor VIVIT, or by knockdown with small interfering RNA (siRNA). Osteogenic transdifferentiation was assessed by gene expression, matrix mineralisation and alkaline phosphatase activity. RESULTS: Exposure to oxLDL caused the transformation of HCASMCs towards an osteoblast-like phenotype based on increased mineral matrix formation and RUNX2 expression. NFATc1 blockade completely prevented oxLDL-induced osteogenic transformation of HCASMCs as well as oxLDL-induced stimulation of osteoblast differentiation. In contrast, matrix mineralisation induced by osteogenic medium was independent of the NFAT pathway. Of note, oxLDL-conditioned medium from HCASMCs transferred to bone cells promoted osteoblast mineralisation. Consistent with these in vitro findings, diabetic rats with a twofold increase in oxidised lipid levels displayed higher aortic calcium concentrations and increased expression of osteogenic markers and production of NFATc1. CONCLUSIONS/INTERPRETATION: Our results identify the NFAT signalling pathway as a novel regulator of oxLDL-induced transdifferentiation of vascular smooth muscle cells towards an osteoblast-like phenotype.


Subject(s)
Calcinosis/metabolism , Lipoproteins, LDL/pharmacology , Muscle, Smooth, Vascular/cytology , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/metabolism , NFATC Transcription Factors/metabolism , Animals , Calcinosis/chemically induced , Cell Differentiation/drug effects , Cell Survival/drug effects , Cells, Cultured , Core Binding Factor Alpha 1 Subunit/genetics , Core Binding Factor Alpha 1 Subunit/metabolism , Fluorescent Antibody Technique , Humans , Myocytes, Smooth Muscle/cytology , NFATC Transcription Factors/antagonists & inhibitors , NFATC Transcription Factors/genetics , Oligopeptides/pharmacology , Osteoblasts/cytology , Osteoblasts/drug effects , Osteoblasts/metabolism , Oxidative Stress/drug effects , Rats , Rats, Zucker , Real-Time Polymerase Chain Reaction
16.
Horm Metab Res ; 43(6): 404-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21557152

ABSTRACT

Research in osteoporosis, which is a complex systemic disease, demands suitable large animal models. In pigs, most research has been done in growing minipigs, which probably are not ideal models for postmenopausal osteoporosis. Therefore, our aim was to analyze the effects of ovariectomy (OVX) and nutritive calcium shortage on multiparous Large White sows. 32 animals were randomly assigned to 4 groups in a cross design with OVX vs. sham and physiological calcium supplementation (0.75% calcium) vs. dietary calcium shortage (0.3% calcium). The observation period was 10 months with blood sampling every 2 months for hematological, immunological, and biochemical bone marker measurements. At the termination of the experiment, animals were sacrificed. Samples of trabecular bone of distal radius, proximal tibia, and sixth lumbar vertebra were subjected to micro-computed tomography imaging and ashed afterwards. Dual X-ray absorptiometry scans of the proximal femora were performed with prepared bones being placed in a water bath for mimicking soft tissue. Analyses of bone marker and cytokine profile kinetics, distribution of leukocyte subpopulations, and morphometrical and densitometrical analyses showed no evidence of any impact of OVX or calcium shortage. In conclusion, the skeleton of adult sows of a conventional breed is seemingly protected from effects of OVX and calcium shortage.


Subject(s)
Bone and Bones/immunology , Calcium, Dietary/pharmacology , Immune System/drug effects , Immune System/immunology , Lymphocytes/immunology , Ovariectomy , Parity/immunology , Animals , Biomarkers/blood , Bone Density/drug effects , Bone and Bones/diagnostic imaging , Bone and Bones/drug effects , Densitometry , Female , Hormones/blood , Lymphocytes/drug effects , Nutritive Value , Pregnancy , Sus scrofa , X-Ray Microtomography
17.
Curr Med Chem ; 15(2): 127-36, 2008.
Article in English | MEDLINE | ID: mdl-18220768

ABSTRACT

For many bone and joint diseases in humans, including postmenopausal osteoporosis, rheumatoid arthritis, and ankylosing spondylitis, an immune-mediated etiology has either been proven or is considered as a co-factor in pathogenesis. The identification of the receptor activator of nuclear factor kappaB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG)-interplay and the in-depth characterization of the signaling pathways induced upon RANK activation, including molecules such as TNF receptor-associated factor 6 (TRAF6), nuclear factor-kappaB (NF-kappaB), and signal transducer and activator of T cells (STAT)-3, now promise to give the opportunity to target osteoclastogenesis specifically. Additionally, many byways influencing osteoclastogenesis have been elucidated, thus giving rise to additional therapeutic approaches. These are based mainly upon the effects of diverse cytokines on osteoclast differentiation with interleukin (IL)-17 and interferone (IFN)-gamma being most prominent at the moment. The same applies for the recently established signaling pathways in osteoblastogenesis, which have attracted much attention in the recent years. In this respect, much attention has been attributed towards bone morphogenetic proteins (BMPs) and the Wnt signaling cascade. In this review, an overview on the key molecules, which (could) serve as promising targets for novel therapeutic interventions with the aim of enhancing osteoblast formation or suppressing osteoclast development, is given. Further on, antibody-based therapeutical schemes as well as methodologically novel, albeit predominantly theoretical at the moment, strategies in the fight against immune-mediated osteopathologies are discussed.


Subject(s)
Bone Diseases/physiopathology , Bone Diseases/therapy , Cytokines/metabolism , Joint Diseases/physiopathology , Joint Diseases/therapy , Osteoblasts/physiology , Osteoclasts/physiology , Animals , Bone Diseases/immunology , Bone and Bones/immunology , Bone and Bones/metabolism , Cytokines/immunology , Humans , Joint Diseases/immunology , NF-kappa B/metabolism , Osteoblasts/immunology , Osteoclasts/immunology , Osteoprotegerin/metabolism , RANK Ligand/metabolism , Signal Transduction , TNF Receptor-Associated Factor 6 , Wnt Proteins/metabolism
18.
Health Care Manag Sci ; 4(3): 165-80, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11519843

ABSTRACT

Decisions about HIV prevention and treatment programs are based on factors such as program costs and health benefits, social and ethical issues, and political considerations. AIDS policy models--that is, models that evaluate the monetary and non-monetary consequences of decisions about HIV/AIDS interventions--can play a role in helping policy makers make better decisions. This paper provides an overview of the key issues related to developing useful AIDS policy models. We highlight issues of importance for researchers in the field of AIDS policy modeling as well as for policy makers. These include geographic area, setting, target groups, interventions, affordability and effectiveness of interventions, type and time horizon of policy model, and type of economic analysis. This paper is not intended to be an exhaustive review of the AIDS policy modeling literature, although many papers from the literature are discussed as examples; rather, we aim to convey the composition, achievements, and challenges of AIDS policy modeling.


Subject(s)
Acquired Immunodeficiency Syndrome/prevention & control , Communicable Disease Control , Health Planning , Health Policy , Models, Theoretical , Acquired Immunodeficiency Syndrome/economics , Acquired Immunodeficiency Syndrome/therapy , Counseling , Global Health , Health Services Accessibility/economics , Humans , Policy Making , Treatment Outcome , Universal Precautions
19.
Behav Res Ther ; 33(8): 917-25, 1995 Nov.
Article in English | MEDLINE | ID: mdl-7487851

ABSTRACT

It has been suggested that neurotic patients engage in 'emotional reasoning', i.e. draw invalid conclusions about a situation on the basis of their subjective emotional response. The present experiment investigated whether anxiety patients infer danger on the basis of their anxious response, whereas normals infer danger only on the basis of objective information. Four groups of anxiety patients (52 spider phobics, 41 panic patients, 38 social phobics, and 31 other anxiety patients) and 24 normal controls made ratings of the danger they perceived in scripts in which information about objective safety vs objective danger, and anxiety response vs non-anxiety response information were systematically varied. As hypothesized, anxiety patients were not only influenced by objective danger information, but also by anxiety response information, whereas normal controls were not. The effect was neither situation-specific, nor specific for panic patients. This tendency to infer danger on the basis of subjective anxiety ('ex-consequentia reasoning') may play a role in the development and maintenance of anxiety disorders.


Subject(s)
Anxiety Disorders/psychology , Arousal , Awareness , Adult , Anxiety Disorders/diagnosis , Anxiety Disorders/therapy , Female , Humans , Internal-External Control , Male , Obsessive-Compulsive Disorder/diagnosis , Obsessive-Compulsive Disorder/psychology , Obsessive-Compulsive Disorder/therapy , Panic Disorder/diagnosis , Panic Disorder/psychology , Panic Disorder/therapy , Personality Assessment , Phobic Disorders/diagnosis , Phobic Disorders/psychology , Phobic Disorders/therapy , Stress Disorders, Post-Traumatic/diagnosis , Stress Disorders, Post-Traumatic/psychology , Stress Disorders, Post-Traumatic/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...